Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

References for PMC Articles for PubMed (Select 21407865)

1.

Olanzapine: a basic science update.

Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO.

Br J Psychiatry Suppl. 1999;(37):36-40. Review.

PMID:
10211140
2.

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.

Tollefson GD, Sanger TM, Lu Y, Thieme ME.

Arch Gen Psychiatry. 1998 Mar;55(3):250-8. Erratum in: Arch Gen Psychiatry 1998 Nov;55(11):1052.

PMID:
9510219
3.

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM.

J Clin Psychiatry. 1997 May;58(5):205-11. Erratum in: J Clin Psychiatry 1997 Jun;58(6):275.

PMID:
9184614
4.

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen JN.

Eur Neuropsychopharmacol. 1997 May;7(2):125-37.

PMID:
9169300
5.
6.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.

Am J Psychiatry. 1997 Apr;154(4):457-65.

PMID:
9090331
7.

Side effect profiles of new antipsychotic agents.

Casey DE.

J Clin Psychiatry. 1996;57 Suppl 11:40-5; discussion 46-52. Review.

PMID:
8941170
8.

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.

Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S.

Psychopharmacology (Berl). 1996 Mar;124(1-2):159-67.

PMID:
8935812
9.

Neurocircuitries and neurotransmitter interactions in schizophrenia.

Carlsson A.

Int Clin Psychopharmacol. 1995 Sep;10 Suppl 3:21-8. Review.

PMID:
8866762
10.

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S.

Neuropsychopharmacology. 1996 Feb;14(2):111-23.

11.

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT.

Neuropsychopharmacology. 1996 Feb;14(2):87-96.

12.

Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?

Harrow M, Yonan CA, Sands JR, Marengo J.

Schizophr Bull. 1994;20(2):327-38.

13.

Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo.

Hemrick-Luecke SK, Snoddy HD, Fuller RW.

Life Sci. 1994;55(7):479-83.

PMID:
8041227
14.

Clozapine: is another view valid?

Meltzer HY.

Am J Psychiatry. 1995 Jun;152(6):821-5. No abstract available.

PMID:
7755109
15.

Drug development and the deficit syndrome of schizophrenia.

Kirkpatrick B, Carpenter WT Jr.

Biol Psychiatry. 1995 Sep 1;38(5):277-8. No abstract available.

PMID:
7495920
16.

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.

Heinrichs DW, Hanlon TE, Carpenter WT Jr.

Schizophr Bull. 1984;10(3):388-98.

17.

A rating scale for extrapyramidal side effects.

Simpson GM, Angus JW.

Acta Psychiatr Scand Suppl. 1970;212:11-9. No abstract available.

PMID:
4917967
18.

Treatment of schizophrenia.

Kane JM.

Schizophr Bull. 1987;13(1):133-56.

19.

Do negative symptoms respond to pharmacological treatment?

Kane JM, Mayerhoff D.

Br J Psychiatry Suppl. 1989 Nov;(7):115-8. Review. No abstract available.

PMID:
2575914
20.

A rating scale for drug-induced akathisia.

Barnes TR.

Br J Psychiatry. 1989 May;154:672-6.

PMID:
2574607
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk